PARP inhibitor-based first-line maintenance therapy for newly diagnosed advanced ovarian cancer across molecular subgroups: an updated systematic review and network meta-analysis. [PDF]
Front OncolFeng J, Qin X, Mo X.
europepmc +1 more source
Journal of Genetic Counseling, Volume 35, Issue 5, October 2026.ABSTRACT The expanding use of whole genome sequencing (WGS) and whole exome sequencing (WES) underscores the need to better understand the psychosocial impact of receiving a broader range of potential results than those generated by other types of genetic testing.
Monica Albu +2 more
wiley +1 more source
PARP Inhibitor Sensitivity in Tumors Harboring Non-BRCA Homologous Recombination Gene Alterations: Current Evidence Across Ovarian, Breast, Prostate, and Pancreatic Cancers. [PDF]
Int J Mol SciDos Santos ES +5 more
europepmc +1 more source
MedComm, Volume 7, Issue 10, October 2026.Cooccurrence of dMMR and HRD in colorectal cancer. On the left blue shaded area, the dMMR (deficient mismatch repair) pathway is shown as a result of the loss of key DNA repair genes MLH1, MSH2, MSH6, and PMS2, which cause single strand breaks.
Xu Zhang +3 more
wiley +1 more source
Platinum cross-resistance after first-line PARPi maintenance in ovarian cancer: a review and proposed redefinition of platinum resistance. [PDF]
Front PharmacolMei R, Song L.
europepmc +1 more source
Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer
MedComm, Volume 7, Issue 10, October 2026.Mesothelin overexpression activate important pathways like nuclear factor k‐light‐chain‐enhancer of activated B cells (NF‐κB) and interleukin‐6 (IL‐6). This in turn causes numerous cancers, such as pancreatic and ovarian cancers. MSLN‐targeting immunotherapies, like monoclonal antibodies, have shown efficacy.
Manoj Kumar Gupta +2 more
wiley +1 more source
TACC3, correlated with immune cell infiltrates, is a novel prognostic biomarker in BRCA. [PDF]
Medicine (Baltimore)Li Z, Zhou X, Wu X, Li H, Zhou C.
europepmc +1 more source
Targeting the DNA Damage Response in Cancer
MedComm, Volume 7, Issue 10, October 2026.Targeting the DNA damage response (DDR) reshapes both tumor vulnerability and antitumor immunity. DNA lesions and DDR inhibitors can promote cytosolic nucleic‐acid sensing, antigen presentation, and immune activation, but can also induce adaptive immune escape.
Yihuan Qiao +4 more
wiley +1 more source
<i>WWOX/HIF1A</i> Balance Delineates Context-Dependent Molecular States in Breast Cancer Subtypes and Ovarian Carcinoma. [PDF]
Int J Mol SciHammouz RY, Maciejek K, Bednarek AK.
europepmc +1 more source